Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CTMX CytomX Therapeutics	$2.28 +8.6%	$2.24	$0.40 ▼ $3.10	$376.00M	2.18	3.84 million shs	4.24 million shs
EGRX Eagle Pharmaceuticals	$3.03 -1.3%	$3.29	$1.50 ▼ $3.87	$39.35M	0.83	6,358 shs	857 shs
SXTC China SXT Pharmaceuticals	$1.61 +16.7%	$1.61	$0.95 ▼ $7.84	$160.12M	1.35	23,835 shs	9.32 million shs
VYGR Voyager Therapeutics	$4.24 +9.3%	$3.37	$2.64 ▼ $8.27	$235.19M	0.9	610,432 shs	1.37 million shs

Analysts Agree—These Gold Picks Outshine the Rest

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CTMX CytomX Therapeutics	+8.57%	+11.76%	+5.07%	-13.64%	+82.40%
EGRX Eagle Pharmaceuticals	-1.30%	-1.94%	-5.02%	+34.67%	-34.27%
SXTC China SXT Pharmaceuticals	+16.67%	+10.27%	+7.33%	-22.97%	-66.51%
VYGR Voyager Therapeutics	+9.28%	+26.19%	+24.71%	+19.77%	-31.61%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CTMX CytomX Therapeutics	$2.28 +8.6%	$2.24	$0.40 ▼ $3.10	$376.00M	2.18	3.84 million shs	4.24 million shs
EGRX Eagle Pharmaceuticals	$3.03 -1.3%	$3.29	$1.50 ▼ $3.87	$39.35M	0.83	6,358 shs	857 shs
SXTC China SXT Pharmaceuticals	$1.61 +16.7%	$1.61	$0.95 ▼ $7.84	$160.12M	1.35	23,835 shs	9.32 million shs
VYGR Voyager Therapeutics	$4.24 +9.3%	$3.37	$2.64 ▼ $8.27	$235.19M	0.9	610,432 shs	1.37 million shs

Analysts Agree—These Gold Picks Outshine the Rest

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CTMX CytomX Therapeutics	+8.57%	+11.76%	+5.07%	-13.64%	+82.40%
EGRX Eagle Pharmaceuticals	-1.30%	-1.94%	-5.02%	+34.67%	-34.27%
SXTC China SXT Pharmaceuticals	+16.67%	+10.27%	+7.33%	-22.97%	-66.51%
VYGR Voyager Therapeutics	+9.28%	+26.19%	+24.71%	+19.77%	-31.61%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CTMX CytomX Therapeutics	3.00	Buy	$5.75	152.19% Upside
EGRX Eagle Pharmaceuticals	0.00	N/A	N/A	N/A
SXTC China SXT Pharmaceuticals	0.00	N/A	N/A	N/A
VYGR Voyager Therapeutics	3.13	Buy	$13.25	212.43% Upside

Current Analyst Ratings Breakdown

Latest EGRX, CTMX, SXTC, and VYGR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
8/7/2025	VYGR Voyager Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$9.00 ➝ $8.00
7/31/2025	CTMX CytomX Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$7.00

(Data available from 9/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CTMX CytomX Therapeutics	$141.10M	2.66	$0.39 per share	5.80	($0.01) per share	-228.00
EGRX Eagle Pharmaceuticals	$257.55M	0.15	$7.58 per share	0.40	N/A	∞
SXTC China SXT Pharmaceuticals	$1.74M	107.36	N/A	N/A	$21.35 per share	0.08
VYGR Voyager Therapeutics	$42.58M	5.52	N/A	N/A	$5.49 per share	0.77

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CTMX CytomX Therapeutics	$31.87M	$0.56	4.07	N/A	N/A	34.04%	158.70%	36.04%	11/6/2025 (Estimated)
EGRX Eagle Pharmaceuticals	$35.64M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
SXTC China SXT Pharmaceuticals	-$3.30M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
VYGR Voyager Therapeutics	-$65M	-$1.85	N/A	N/A	N/A	-253.49%	-37.65%	-28.89%	11/11/2025 (Estimated)

Latest EGRX, CTMX, SXTC, and VYGR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/6/2025	Q2 2025	VYGR Voyager Therapeutics	-$0.48	-$0.57	-$0.09	-$0.57	$9.50 million	$5.20 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CTMX CytomX Therapeutics	N/A	N/A	N/A	N/A	N/A
EGRX Eagle Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SXTC China SXT Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
VYGR Voyager Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CTMX CytomX Therapeutics	N/A	4.20	4.20
EGRX Eagle Pharmaceuticals	N/A	N/A	N/A
SXTC China SXT Pharmaceuticals	0.01	3.54	3.40
VYGR Voyager Therapeutics	N/A	5.43	5.43

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CTMX CytomX Therapeutics	67.77%
EGRX Eagle Pharmaceuticals	85.36%
SXTC China SXT Pharmaceuticals	5.02%
VYGR Voyager Therapeutics	48.03%

Insider Ownership

Company	Insider Ownership
CTMX CytomX Therapeutics	6.60%
EGRX Eagle Pharmaceuticals	28.90%
SXTC China SXT Pharmaceuticals	3.95%
VYGR Voyager Therapeutics	6.39%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CTMX CytomX Therapeutics	170	164.91 million	154.03 million	Optionable
EGRX Eagle Pharmaceuticals	100	12.99 million	9.23 million	No Data
SXTC China SXT Pharmaceuticals	90	116.03 million	111.45 million	Not Optionable
VYGR Voyager Therapeutics	100	55.47 million	51.93 million	Optionable

EGRX, CTMX, SXTC, and VYGR Headlines

Recent News About These Companies

Voyager Therapeutics, Inc. (VYGR) Presents At Citi's Biopharma Back To School Conference Transcript

September 2, 2025 | seekingalpha.com

Voyager Therapeutics, Inc. (NASDAQ:VYGR) Receives $13.25 Average Price Target from Analysts

August 27, 2025 | americanbankingnews.com

Voyager to Present at Upcoming Investor Conferences

August 26, 2025 | globenewswire.com

Voyager Therapeutics, Inc. (NASDAQ:VYGR) Receives Consensus Recommendation of "Buy" from Analysts

August 26, 2025 | marketbeat.com

Voyager Therapeutics Extends Cash Runway to 2028

August 13, 2025 | msn.com

Truist Financial Keeps Their Buy Rating on Voyager Therapeutics (VYGR)

August 11, 2025 | theglobeandmail.com

Voyager Therapeutics (VYGR) Receives a Buy from Oppenheimer

August 11, 2025 | theglobeandmail.com

Equities Analysts Offer Predictions for VYGR Q3 Earnings

August 11, 2025 | marketbeat.com

Voyager Therapeutics (NASDAQ:VYGR) Releases Earnings Results, Misses Estimates By $0.09 EPS

August 10, 2025 | marketbeat.com

Voyager Therapeutics (VYGR) Receives a Buy from Canaccord Genuity

August 9, 2025 | theglobeandmail.com

Voyager Therapeutics (NASDAQ:VYGR) Price Target Lowered to $8.00 at Wedbush

August 8, 2025 | marketbeat.com

Voyager Therapeutics (VYGR) Reports Q2 Loss, Lags Revenue Estimates

August 6, 2025 | zacks.com

Voyager Reports Second Quarter 2025 Financial and Operating Results

August 6, 2025 | globenewswire.com

Voyager 1 and 2: From Earth to Interstellar Space: The Final Frontier Awaits

July 21, 2025 | msn.com

Read the NASA ‘Voyager Declaration’ Letter of Dissent

July 21, 2025 | nytimes.com

Mascarene Partners Acquires Voyager Trucking

July 18, 2025 | finance.yahoo.com

Mascarene buys US waste services company Voyager Trucking

July 18, 2025 | realassets.ipe.comR

Voyager Therapeutics adds new gene therapy to Alzheimer’s program

July 18, 2025 | bioworld.comB

Mascarene to acquire waste services transport firm Voyager Trucking Corporation

July 18, 2025 | pehub.com

Looking Beyond Voyager 1 And 2

July 17, 2025 | msn.com

Robert Beltran on Star Trek: I “Risked being fired” Because I Didn’t Like What Was Happening in the Last 3 Years of Voyager

July 16, 2025 | fandomwire.comF

New MarketBeat Followers Over Time

Media Sentiment Over Time

EGRX, CTMX, SXTC, and VYGR Company Descriptions

CytomX Therapeutics NASDAQ:CTMX

$2.28 +0.18 (+8.57%)

Closing price 09/5/2025 04:00 PM Eastern

Extended Trading

$2.30 +0.02 (+0.66%)

As of 09/5/2025 06:51 PM Eastern

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

Eagle Pharmaceuticals NASDAQ:EGRX

$3.03 -0.04 (-1.30%)

As of 09/5/2025 03:58 PM Eastern

Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.

China SXT Pharmaceuticals NASDAQ:SXTC

$1.61 +0.23 (+16.67%)

Closing price 09/5/2025 04:00 PM Eastern

Extended Trading

$1.56 -0.06 (-3.42%)

As of 09/5/2025 07:10 PM Eastern

China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company had an end-customer base of pharmaceutical companies, chain pharmacies, and hospitals in 10 provinces and municipalities in China. China SXT Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Taizhou, China.

Voyager Therapeutics NASDAQ:VYGR

$4.24 +0.36 (+9.28%)

Closing price 09/5/2025 04:00 PM Eastern

Extended Trading

$4.19 -0.05 (-1.16%)

As of 09/5/2025 07:54 PM Eastern

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest EGRX, CTMX, SXTC, and VYGR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest EGRX, CTMX, SXTC, and VYGR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

EGRX, CTMX, SXTC, and VYGR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

EGRX, CTMX, SXTC, and VYGR Company Descriptions

CytomX Therapeutics NASDAQ:CTMX

Eagle Pharmaceuticals NASDAQ:EGRX

China SXT Pharmaceuticals NASDAQ:SXTC

Voyager Therapeutics NASDAQ:VYGR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest EGRX, CTMX, SXTC, and VYGR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest EGRX, CTMX, SXTC, and VYGR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

EGRX, CTMX, SXTC, and VYGR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

EGRX, CTMX, SXTC, and VYGR Company Descriptions

CytomX Therapeutics NASDAQ:CTMX

Eagle Pharmaceuticals NASDAQ:EGRX

China SXT Pharmaceuticals NASDAQ:SXTC

Voyager Therapeutics NASDAQ:VYGR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools